[Federal Register Volume 90, Number 11 (Friday, January 17, 2025)]
[Notices]
[Page 5900]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2025-01152]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2023-N-3595]


Agency Information Collection Activities; Proposed Collection; 
Improving the Quality and Representativeness of the Treatment Center 
Program Data--Data Modifications to the Current Survey Instrument 
Format to Minimize Misclassification; Withdrawal of Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; withdrawal.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the 
withdrawal of a notice that was published in the Federal Register of 
October 18, 2023.

DATES: The notice is withdrawn on January 17, 2025.

FOR FURTHER INFORMATION CONTACT: Darren Eicken, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave. Bldg. 51, Rm. 6206, Silver Spring, MD 20993-0002, 240-
402-0978.

SUPPLEMENTARY INFORMATION: In a notice published in the Federal 
Register of October 18, 2023 (88 FR 71875), ``Agency Information 
Collection Activities; Proposed Collection; Comment Request: Improving 
the Quality and Representativeness of the Treatment Center Program 
Data--Data Modifications to the Current Survey Instrument Format to 
Minimize Misclassification.'' FDA requested comment on the information 
collection associated with the proposed study entitled ``Improving the 
Quality and Representativeness of the Treatment Center Program Data--
Data Modifications to the Current Survey Instrument Format to Minimize 
Misclassification.''
    Under the Paperwork Reduction Act of 1995, Federal Agencies are 
required to publish notice in the Federal Register concerning each 
proposed collection of information, including each proposed extension 
of an existing collection of information, and to allow 60 days for 
public comment in response to the notice.
    In the October 18, 2023, Federal Register notice, FDA proposed a 
new collection of information. However, FDA no longer intends to 
proceed with the proposed study due to circumstances and timing 
surrounding the execution of the study. Therefore, we are withdrawing 
the October 18, 2023 notice.

    Dated: January 13, 2025.
P. Ritu Nalubola,
Associate Commissioner for Policy.
[FR Doc. 2025-01152 Filed 1-16-25; 8:45 am]
BILLING CODE 4164-01-P